# US 2010/0144806 A1 · Cyclopropanecarboxylic Acid Compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144806 A1
- Document ID: US20100144806A1
- Status: Published application
- Kind: A1
- Application number: 11/989,748
- Filed: 2006-07-28
- Published: 2010-06-10
- Earliest claimed: 2005-07-29
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Tsuneo Yasuma; Nobuyuki Negoro
- Web page: https://patentgrep.com/patent/US20100144806A1

## CPC

- C07C 229/46: having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 62/34: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 69/757: having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] in the acid moiety
- C07D 277/20: having two or three double bonds between ring members or between ring members and non-ring members
- C07D 277/42: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 305/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
- C07D 335/02: not condensed with other rings
- C07C 2601/02: with a three-membered ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound of the formula (I): wherein each symbol is as defined in the description, a salt s thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonist activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.

## Claims

### Claim 1

A compound represented by the formula:
wherein
ring A is an optionally substituted cyclic group;
ring B is an optionally substituted ring;
V is a bond or a spacer having 1 to 3 atoms in the main chain;
W is an optionally substituted C1-6 alkylene group;
X is O or S;
R1 and R2 are the same or different and each is a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group; and
R3 is an optionally substituted hydroxy group or an optionally substituted amino group,
provided that when V is a bond and W is a methylene group, then ring B should not be oxazole and thiazole,
or a salt thereof, excluding 2-(2-{[6-(benzyloxy)-2-naphthyl]methoxy}phenyl)cyclopropanecarboxylic acid.

### Claim 2 (depends on 1)

A prodrug of a compound of claim 1.

### Claim 3 (depends on 1)

A compound of claim 1, wherein ring B is an optionally substituted benzene ring.

### Claim 4 (depends on 1)

A compound of claim 1, wherein ring A is an optionally substituted phenyl.

### Claim 5 (depends on 1)

A compound of claim 1, wherein ring A is an optionally substituted thiazolyl.

### Claim 6 (depends on 1)

A compound of claim 1, wherein V is
(1) a bond;
(2) —W3—N(RA)—W2—; or
(3) —W3—O—W2—
wherein
W2 and W3 are the same or different and each is a bond or an optionally substituted linear C1-2 alkylene group, and when both of W2 and W3 are optionally substituted linear C1-2 alkylene groups, then the total carbon number of the linear C1-2 alkylene groups constituting W2 and W3 should be 2, and RA is a hydrogen atom or a substituent.

### Claim 7 (depends on 1)

A compound of claim 1, wherein W is

### Claim 8 (depends on 1)

A compound of claim 1, wherein X is O.

### Claim 9 (depends on 1)

A compound of claim 1, wherein R1 and R2 are each a hydrogen atom or a halogen atom.

### Claim 10 (depends on 1)

A compound of claim 1, wherein R3 is a hydroxy group.

### Claim 11 (depends on 1)

A compound of claim 1, which is selected from
2-(4-{[4′-(2-ethoxyethoxy)-2′,6′-dimethylbiphenyl-3-yl]methoxy}phenyl)cyclopropanecarboxylic acid,
2-[4-({4′-[(4′-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy]-2′,6′-dimethylbiphenyl-3-yl}methoxy)phenyl]cyclopropanecarboxylic acid,
2-[4-({2′,6′-dimethyl-4′-[(3-methyloxetan-3-yl)methoxy]biphenyl-3-yl}methoxy)phenyl]cyclopropanecarboxylic acid,
2-[4-({4-[((3-methylbutyl){4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}amino)methyl]benzyl}oxy)phenyl]cyclopropanecarboxylic acid,
2-[4-({4-[(propyl{4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}amino)methyl]benzyl}oxy)phenyl]cyclopropanecarboxylic acid, and salts thereof.

### Claim 12 (depends on 1)

An insulin secretagogue comprising a compound of claim 1 or a prodrug thereof.

### Claim 13 (depends on 1)

A pharmaceutical agent comprising a compound of claim 1 or a prodrug thereof.

### Claim 14 (depends on 1)

An agent for the prophylaxis or treatment of a pathology or disease involving a GPR40 receptor, which comprises a compound of claim 1 or a prodrug thereof.

### Claim 15 (depends on 13)

The pharmaceutical agent of claim 13, which is an agent for the prophylaxis or treatment of diabetes.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method of promoting insulin secretion in a mammal, which comprises administering an effective amount of a compound of claim 1 or a prodrug thereof to the mammal.

### Claim 19 (depends on 1)

A method for the prophylaxis or treatment of a pathology or disease involving a GPR40 receptor in a mammal, which comprises administering an effective amount of a compound of claim 1 or a prodrug thereof to the mammal.
